ZDHHC2 and prostate cancer: Although ZDHHC2 promotes enzalutamide resistance in prostate cancer, the underlying mechanisms remain to be elucidated, so multi‐omics analyses were performed with control and ZDHHC2 knockdown C4‐2 cell lines (Figure 3A).